Page 92 - The Indian Digital Edition September-October 2020

FIGURE 3. BILATERAL THINNING OF THE RETINAL NERVE FIBER LAYER THAT IS GREATER TEMPORALLY, AS SEEN
ON OPTICAL COHERENCE TOMOGRAPHY

TREATMENT eye examinations including visual Institute -- Neuro-Ophthalmology.
field testing and optical coherence Philadelphia, USA: Wolters Kluwer
There is currently no treatment tomography evaluation of the optic Health, 2012:136.
available for patients with DOA nerve and ganglion cell complex to
(3) . Genetic counseling may be monitor for progression of vision 4) Orssaud C. Optic atrophy. Scientific
suggested, although this has limited loss. Emphasis may be placed on Editor: Professor Jean-Louis Dufier.
predictive use as clinical presentation maximising functionality and low Orphanet Encyclopedia; November
2003. Accessed March 2, 2020.
of DOA is diverse within families . vision services should be considered http://www.orpha.net/data/patho/
(6)
Patients should be seen for regular when applicable. GB/uk.OA.pdf.
REFERENCES 5) Lenaers G, Hamel C, Delettre C, et al.
ALTHOUGH BEST 1) Brodsky MC. Pediatric Neuro- Dominant optic atrophy. Orphanet
Journal of Rare Diseases; 2012;7:46.
CHARACTERISED AS Ophthalmology. New York, NY, USA:
A GENETIC OPTIC Springer, 2010: 172-6. 6) Delettre C, Lenaers G, Pelloquin L,
et al. OPA1 (Kjer Type) Dominant
NEUROPATHY, DOA 2) Genetics Home. Optic Atrophy optic atrophy: A novel mitochondrial
IS ALSO A TYPE OF Type 1. Genetics Home Reference. disease. Molecular Genetics
MITOCHONDRIOPATHY Accessed February 24, 2020. https:// and Metabolism; 2001; 75:
97–107. https://doi.org/10.1006/
AND MAY AFFECT ghr.nlm.nih.gov/condition/optic- mgme.2001.3278.
atrophy-type-1.
ANY TISSUES WITH 7) Onofrey BE, Skorin L, Holdeman NR.
MITOCHONDRIA 3) Savino PJ, Danesh-Meyer HV. Ocular Therapeutics Handbook: A
Colour Atlas and Synopsis of Clinical Manual. Philadelphia, USA:
Clinical Ophthalmology -- Wills Eye Wolters Kluwer Health, 2020: 628-32.

| SEPT-OCT 2020 | 88 CLINICAL